Project Grant R01CA299899
Award Date
4/1/25
Completion Date
3/31/30
Dollars Obligated
$550K
Federal Agency
National Cancer Institute
Federal Grant Program
93.396
Assistance Type
Project Grant
Place of Performance
Florida, USA
Similar Awards
The Department of Defense, through the Military Medical Research and Development program (CFDA 12.420), has awarded a $328,575 Project Grant to the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. in Tampa, Florida. This 3-year grant, with a start date of September 1, 2024, will support research aimed at "Reversing Exhaustion of Tumor-Infiltrating Lymphocytes for Improvement of Adoptive Cell Therapy." As a National Cancer Institute-designated comprehensive cancer...
This $460,204.00 federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. (Moffitt Cancer Center) supports research aimed at defining the impact of in situ activation of CD40 and type 1 interferon signaling on the tumor microenvironment and systemic T cell immunity in murine models and cancer patients. The award period runs from May 1, 2024 to April 30, 2029. Moffitt...
This $697,590 federal Project Grant award from the Defense Health Agency (CFDA 12.420 - Military Medical Research and Development program) supports research at the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. (Moffitt Cancer Center) to evaluate B-T cell cross-talk within tertiary lymphoid structures in melanoma progression and immune checkpoint blockade. The grant, with a performance period from July 1, 2024 to June 30, 2027, aims to advance scientific understanding of...
This Project Grant award from the National Cancer Institute (NCI), under the Cancer Treatment Research program (CFDA 93.395), provides $568,538 to the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. (Moffitt Cancer Center) to investigate how the release of interleukin-1 alpha during various cancer therapies, particularly those inducing necrosis or programmed necrosis, can alter the immune response and create an immunosuppressive tumor environment. The research aims to...
The National Cancer Institute (NCI) awarded a $657,121 Project Grant (CFDA 93.395 - Cancer Treatment Research) to the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. (Moffitt Cancer Center) to study the use of dendritic cell therapy as a treatment for leptomeningeal disease (LMD) in breast cancer patients. The grant, awarded on December 12, 2024, will fund research to understand how intrathecal delivery of HER2 and HER3 peptide-pulsed dendritic cells can remodel the...
The Department of Defense's Military Medical Research and Development program (CFDA 12.420) awarded a $2,837,644 Project Grant to the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. in Tampa, Florida. The funding will support "Translational Studies for Targeted Alpha-Particle Therapy for Rare Melanomas" over a 4-year period from September 1, 2023 to August 31, 2027. This project grant aims to advance research into innovative cancer therapies, specifically...
The National Cancer Institute (NCI) awarded a 5-year, $709,554 Project Grant (CFDA 93.395 - Cancer Treatment Research) to Emory University to advance the understanding of how a novel neoadjuvant therapy impacts the immune system in patients with solid tumors, using refractory melanoma as a model. The key objectives are to:
Gain insights on how blocking the Semaphorin 4D (SEMA4D) protein, when combined with immune checkpoint blockade, affects the induction and infiltration of...
This Project Grant award from the National Cancer Institute (NCI), under the Cancer Treatment Research program (CFDA 93.395), is funding research at the H. Lee Moffitt Cancer Center and Research Institute in Tampa, Florida. The $528,175 award aims to identify novel cell surface targets for innovative immunotherapy of multiple myeloma.
The key objectives are to: 1) define the distribution and density of candidate target antigens in multiple myeloma patient samples, especially those who have...
This federal Project Grant award for $995,267 was provided by the Defense Health Agency through the Military Medical Research and Development program (CFDA 12.420). The award was granted to the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. (Moffitt Cancer Center), a non-profit, National Cancer Institute-designated comprehensive cancer center in Tampa, Florida.
The funding supports a 4-year translational cancer research initiative focused on advancing peer-reviewed cancer...
The U.S. Department of Defense's Defense Health Agency awarded a $481,749 Project Grant to the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. (Moffitt Cancer Center) under the Military Medical Research and Development program (CFDA 12.420). The grant, effective September 30, 2023 through September 29, 2026, will support research to dissect the spatial molecular architecture of the transformed cutaneous T cell lymphoma tumor microenvironment, with the goal of identifying...